基本情報
- CAS
146-56-5- 標準SMILES
Cl.Cl.OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1- InChIKey
MBHNWCYEGXQEIT-UHFFFAOYSA-N- 分子式
- C22H28Cl2F3N3OS
- 平均分子量
- 510.4 g/mol
- 単同位体質量
- 509.1282236
概要
Fluphenazine hydrochloride is a member of phenothiazines. It has a role as an anticoronaviral agent.
名称と識別子
- 優先名称
- Fluphenazine Hydrochloride
- IUPAC
- 2-[4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]piperazin-1-yl]ethanol;dihydrochloride
- 現地名
- フルフェナジン·二塩酸
- 英語名
- Fluphenazine hydrochloride
- 分子式
- C22H28Cl2F3N3OS
- 分子量
- 510.44
名称と別名
Fluphenazine dihydrochlorideFluphenazine hydrochloride146-56-5PermitilFLUPHENAZINE HCLDapotumSquibb 4918ZOU145W1XLFluphenazini hydrochloridumNSC-179197DTXSID008929224-(3-(2-(Trifluoromethyl)phenothiazin-10-yl)propyl)-1-piperazineethanol dihydrochloride
名称をさらに表示
フルフェナジン·2塩酸塩フルフェナジン二塩酸塩フルフェナジン塩酸塩フルフェナジン·二塩酸塩酸フルフェナジンフルフェナジン二塩酸塩FLUPHENAZINE DECANOATE EP IMPURITY Bフルフェナジン 塩酸塩塩酸フルフェナジン (JAN)ProlinateomcaanatensolFluphenazine DiHCla4077liogenmoditen
4-[3-[2-(Trifluoromethyl)phenothiazin-10-yl]propyl]-1-piperazineethanol dihydrochlorideNSC179197RefChem:55217Fluphenazine HydrochorideHydrochloride, FluphenazineDTXCID401284964205-674-1Prolixin
データベース識別子
物性
構造計算による物性
- 極性表面積
- 55.3 Ų
- 水素結合供与体数
- 3
- 水素結合受容体数
- 8
- 回転可能結合数
- 6
- 重原子数
- 32
- 形式電荷
- 0
- 複雑度
- 544
実験および物理化学的性質
Human Drugs
Breast Feeding; Lactation; Milk, Human; Antipsychotic Agents; Phenothiazines
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
Collision Cross Section197.5 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
物理化学的性質
- 融点
- 200 · 200-2020C
- 貯蔵温度
- 2 · 2-8°C
- 溶解性
- DMSO、メタノールに可溶。
- 外見
- Solid
- 色
- White to Light yellow
- 安定性
- Hygroscopic
- 主な用途
- 医薬品（低分子化合物）
- InChI
- InChI=1S/C22H26F3N3OS.2ClH/c23-22(24,25)17-6-7-21-19(16-17)28(18-4-1-2-5-20(18)30-21)9-3-8-26-10-12-27(13-11-26)14-15-29;;/h1-2,4-7,16,29H,3,8-15H2;2*1H
- InChIKey
- MBHNWCYEGXQEIT-UHFFFAOYSA-N
- SMILES
- C12=CC(=CC=C1SC1C=CC=CC=1N2CCCN1CCN(CCO)CC1)C(F)(F)F.Cl.Cl
- EPAの化学物質情報
- Fluphenazine dihydrochloride (146-56-5)
化学的性質
安全と法規制
安全情報は参考情報です。供給元の安全データシート（SDS）、適用法令、専門家による評価に代わるものではありません。
GHS分類
GHS Classification
Danger
H301 (68.2%): Toxic if swallowed [Danger Acute toxicity, oral]
P203, P260, P261, P263, P264, P264+P265, P270, P271, P272, P280, P284, P301+P316, P301+P317, P302+P352, P304+P340, P305+P354+P338, P308+P316, P316, P317, P318, P319, P320, P321, P330, P332+P317, P333+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 66 reports by companies from 8 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
危険有害性情報
Regulatory Information1-Piperazineethanol, 4-3-2-(trifluoromethyl)-10H-phenothiazin-10-ylpropyl-, dihydrochloride: Does not have an individual approval but may be used under an appropriate group standard
Other Safety InformationIMAP assessments - 1-Piperazineethanol, 4-[3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl]-, dihydrochloride: Human health tier I assessment
Hazard Classes and CategoriesAcute Tox. 3 (68.2%)
毒性情報
Exposure RoutesOral, Intramuscular
Toxicity Summary
Fluphenazine blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis.
Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
化学と産業
薬理情報
FDA Pharmacological Classification
FLUPHENAZINE HYDROCHLORIDE
Phenothiazines [CS]; Phenothiazine [EPC]
MeSH Pharmacological Classification
Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus.
Drugs that bind to but do not activate DOPAMINE RECEPTORS, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as ANTIEMETICS, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with NEUROLEPTIC MALIGNANT SYNDROME.
用途と製造
UsesFor management of manifestations of psychotic disorders.
応用分野
使用Antipsychotic
一般的な説明The member ofthe piperazine subgroup with a trifluoromethyl group at the2-position of the phenothiazine system and the most potentantipsychotic phenothiazine on a milligram basis is fluphenazinehydrochloride, 4-[3-[2-(trifluoromethyl)phenazin-10-yl] propyl]-1-piperazineethanol dihydrochloride, 10[3-[4-(2-hydroxyethyl)piperazinyl]propyl]-2-trifluoromethylphenothiazine dihydrochloride (Permitil, Prolixin). It is alsoavailable as two lipid-soluble esters for depot intramuscularinjection, the enanthate (heptanoic acid ester) and the decanoateester. These long-acting preparations have use intreating psychotic patients who do not take their medicationor are subject to frequent relapse.
関連反応
0 件
現在のフィルター条件では反応記録がありません。
化合物ノート
読み込み中…